Clinical use of OKT3: The role of cytokine release and xenosensitization
- 31 December 1988
- journal article
- Published by Elsevier in Journal of Autoimmunity
- Vol. 1 (6), 631-640
- https://doi.org/10.1016/0896-8411(88)90054-6
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Detection of Circulating Tumor Necrosis Factor after Endotoxin AdministrationNew England Journal of Medicine, 1988
- PREVENTION OF REJECTION OF KIDNEY TRANSPLANTS BY MONOCLONAL ANTIBODY DIRECTED AGAINST INTERLEUKIN 2The Lancet, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- The immune response against therapeutic monoclonal antibodiesImmunology Today, 1986
- The Human Immune Response to the OKT3 Monoclonal Antibody Is OligoclonalScience, 1986
- Fine specificity of antibodies produced in rhesus monkeys following in vivo treatment with anti‐T cell murine monoclonal antibodiesEuropean Journal of Immunology, 1986
- A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal TransplantsNew England Journal of Medicine, 1985
- Unusually restricted anti‐isotype human immune response to OKT3 monoclonal antibodyEuropean Journal of Immunology, 1984
- REVERSAL OF TRANSPLANT REJECTION BY MONOCLONAL ANTIBLAST ANTIBODYThe Lancet, 1983
- EFFECTS OF IN VIVO ADMINISTRATION OF MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN T CELL SUBPOPULATIONS ON THE IMMUNE SYSTEM IN A RHESUS MONKEY MODELTransplantation, 1983